Analysts Blame Affy's 'Disappointing' Q2 Revenues on Sequencing Adoption, Loss of Market Share

Affy officials attributed the decline on weakness in sales to academic customers, especially in North America. Analysts, however, linked the limp performance with increased adoption of next-generation sequencing and array competition from its chief rival, Illumina.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.